These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3765657)

  • 1. The metabolism of 14C-oxcarbazepine in man.
    Schütz H; Feldmann KF; Faigle JW; Kriemler HP; Winkler T
    Xenobiotica; 1986 Aug; 16(8):769-78. PubMed ID: 3765657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of glucuronide metabolites of carbamazepine in human urine by gas chromatography and mass spectrometry.
    Lynn RK; Smith RG; Thompson RM; Deinzer ML; Griffin D; Gerber N
    Drug Metab Dispos; 1978; 6(4):494-501. PubMed ID: 28932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the clinical pharmacokinetics of oxcarbazepine.
    Flesch G
    Clin Drug Investig; 2004; 24(4):185-203. PubMed ID: 17516704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man.
    Malátková P; Havlíková L; Wsól V
    Chem Biol Interact; 2014 Sep; 220():241-7. PubMed ID: 25063510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic fate of [14C]oxaprotiline.HCl in man. II. Isolation and identification of metabolites.
    Dieterle W; Faigle JW; Kriemler HP; Winkler T
    Xenobiotica; 1984 Apr; 14(4):311-9. PubMed ID: 6464501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
    Volosov A; Xiaodong S; Perucca E; Yagen B; Sintov A; Bialer M
    Clin Pharmacol Ther; 1999 Dec; 66(6):547-53. PubMed ID: 10613609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence and fate of carbamazepine, oxcarbazepine, and seven of their metabolites at wastewater treatment plants.
    Leclercq M; Mathieu O; Gomez E; Casellas C; Fenet H; Hillaire-Buys D
    Arch Environ Contam Toxicol; 2009 Apr; 56(3):408-15. PubMed ID: 18779941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-reactivity assessment of oxcarbazepine and its metabolites in the EMIT assay of carbamazepine plasma levels.
    Kumps A; Mardens Y
    Ther Drug Monit; 1986; 8(1):95-7. PubMed ID: 3515642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disposition and metabolism of 14C-oxprenolol.HCl in man.
    Dieterle W; Faigle JW; Küng W; Theobald W
    Xenobiotica; 1986 Feb; 16(2):181-91. PubMed ID: 3515777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.
    Ambrósio AF; Soares-Da-Silva P; Carvalho CM; Carvalho AP
    Neurochem Res; 2002 Feb; 27(1-2):121-30. PubMed ID: 11926264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography.
    Pienimäki P; Fuchs S; Isojärvi J; Vähäkangas K
    J Chromatogr B Biomed Appl; 1995 Nov; 673(1):97-105. PubMed ID: 8925080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine.
    Marchi N; Guiso G; Rizzi M; Pirker S; Novak K; Czech T; Baumgartner C; Janigro D; Caccia S; Vezzani A
    Epilepsia; 2005 Oct; 46(10):1613-9. PubMed ID: 16190932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy.
    Di Resta C; Ambrosi P; Curia G; Becchetti A
    Eur J Pharmacol; 2010 Sep; 643(1):13-20. PubMed ID: 20561518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry.
    Maggs JL; Pirmohamed M; Kitteringham NR; Park BK
    Drug Metab Dispos; 1997 Mar; 25(3):275-80. PubMed ID: 9172943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma.
    Fortuna A; Sousa J; Alves G; Falcão A; Soares-da-Silva P
    Anal Bioanal Chem; 2010 Jun; 397(4):1605-15. PubMed ID: 20401721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
    Almeida L; Soares-da-Silva P
    J Clin Pharmacol; 2004 Aug; 44(8):906-18. PubMed ID: 15286095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolism and excretion of (+)-[14C]cyanidanol-3 in man following oral administration.
    Hackett AM; Griffiths LA; Broillet A; Wermeille M
    Xenobiotica; 1983 May; 13(5):279-86. PubMed ID: 6636824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers.
    Theisohn M; Heimann G
    Eur J Clin Pharmacol; 1982; 22(6):545-51. PubMed ID: 7128666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024.
    Ambrósio AF; Silva AP; Araújo I; Malva JO; Soares-da-Silva P; Carvalho AP; Carvalho CM
    Eur J Pharmacol; 2000 Oct; 406(2):191-201. PubMed ID: 11020481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.